Researchers from the University of Tübingen, Stanford University, Emory University, and Cincinnati Children’s Hospital Medical Center have conducted a study on infant immune responses to SARS-CoV-2 infections. The study, published in Cell, found that infants and young children have durable antibody responses against SARS-CoV-2 for up to 300 days.
The research team aimed to understand how infants and young children develop immune responses to SARS-CoV-2. They conducted a comprehensive, longitudinal analysis by collecting blood and nasal swab samples from infants and young children in the IMPRINT cohort at Cincinnati Children’s Hospital Medical Center. The cohort included 54 infected infants and young children, as well as 27 healthy control infants. The control group consistently tested negative for SARS-CoV-2.
The study compared the immune responses of infants and young children to those of adult COVID-19 patients and healthy controls. It found that infants and young children showed robust and long-lasting antibody responses to SARS-CoV-2 compared to adults. They also displayed an upregulation of activation markers on innate cells, but no significant increase in inflammatory cytokines.
While infants had lower memory B and T cell responses compared to adults, they showed an increase in multifunctional T helper 17 and 1-type CD4+ T cells. Additionally, infants mounted a strong mucosal immune response characterized by inflammatory cytokines, interferon α, and markers associated with T helper 17 and neutrophil responses, particularly in the nasal mucosa.
These findings suggest that vaccine formulations could be designed to take advantage of these innate immune system activation pathways to prevent unwanted inflammation. The study contributes to our understanding of infant immune responses to SARS-CoV-2 and has implications for vaccine development.
Overall, this research provides valuable insights into how infants and young children respond to SARS-CoV-2 infections and highlights the potential for developing effective vaccines tailored to their unique immune responses. The study’s findings have important implications for protecting this vulnerable population and mitigating the impact of COVID-19 on infants and young children.